GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: APL-1202 | APL1202 | compound 10 [PMID: 30939017]
nitroxoline is an approved drug
Compound class:
Synthetic organic
Comment: Nitroxoline is an antimicrobial used to treat urinary tract infections [3]. Repurposing of nitroxoline for infectious diseases and oncological indications has been proposed, although pharmacokinetic challenges are likely to hamper clinical translation.
From a patent it would appear that Healx Ltd. are interested in pursuing nitroxoline for the treatment of plexiform neurofibroma/neurofibromatosis type 1 (NF1) [1]. Review of Healx's active pipeline (January 2026) reveals two candidates with codes HLX-1502 and HLX-0213 in development for NF1 [4]. HLX-1502 has reached phase 2 whereas HLX-0213 is in the discovery phase (at time of writing), so it is plausible that HLX-1502 is nitroxoline. We await formal disclosure of this potential association. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Brown D. (2025)
Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma. Patent number: US20250000852A1. Assignee: Healx Ltd. Priority date: 18/11/2022. Publication date: 02/01/2025. |
|
2. Deng Y, Wu L, Pan K. (2020)
Nitroxoline prodrug and use thereof. Patent number: CA3113463A1. Assignee: Jiangsu Yahong Meditech Co Ltd. Priority date: 27/09/2019. Publication date: 02/04/2020. |
|
3. FUSON RC, BAUMAN RA et al.. (1947)
The synthesis of 5-hydroxy-8-nitroquinoline and certain of its derivatives. J Org Chem, 12 (6): 799-806. [PMID:18919732] |
|
4. Healx.
Pipeline. Accessed on 19/01/2026. Modified on 19/01/2026. https://healx.ai, https://healx.ai/pipeline/ |
|
5. Heinrich T, Seenisamy J, Blume B, Bomke J, Calderini M, Eckert U, Friese-Hamim M, Kohl R, Lehmann M, Leuthner B et al.. (2019)
Discovery and Structure-Based Optimization of Next-Generation Reversible Methionine Aminopeptidase-2 (MetAP-2) Inhibitors. J Med Chem, 62 (10): 5025-5039. [PMID:30939017] |
|
6. Liu JO, Shim JS, Chong CR, Bhat S. (2014)
Quinoline compounds as inhibitors of angiogenesis, human methionyl aminopeptidase, and SIRT1, and methods of treating disorders. Patent number: US8729097B2. Assignee: Johns Hopkins University. Priority date: 06/10/2009. Publication date: 20/05/2014. |